BioNTech Faces FDA Intervention in Lung Cancer Trial
BioNTech SE has encountered a significant hurdle in its development of a lung cancer treatment. The company has been informed by its partner, OncoC4 Inc., that the FDA has instituted a partial clinical hold on the Phase 3 PRESERVE-003 trial.
Details of the Clinical Trial
This open-label, randomized study examines BNT316/ONC-392 (gotistobart) as a potential monotherapy for patients battling metastatic non-small cell lung cancer (NSCLC) who have not responded positively to prior treatments involving PD-(L)1 inhibitors.
Reasons Behind the Clinical Hold
The partial hold comes after an independent data monitoring committee noted varying outcomes in patients diagnosed with squamous compared to non-squamous NSCLC. BioNTech disclosed this information in its recent regulatory filing. Due to these discrepancies, both BioNTech and OncoC4 decided to halt new patient enrollment while consulting with the FDA about subsequent steps.
Current Patient Treatment Status
While new enrollments are on pause, patients who are already part of the trial will continue their treatment as planned. Importantly, the trials of BNT316/ONC-392 for other indications remain unaffected by this decision.
Previous FDA Holds on BioNTech Trials
This isn't the first instance where BioNTech's trials faced scrutiny. Earlier this year, its partner MediLink Therapeutics (Suzhou) Co., Ltd also experienced a partial clinical hold from the FDA on the Phase 1 trial of BNT326/YL202, which targets heavily pre-treated patients suffering from advanced or metastatic forms of cancer, such as epidermal growth factor receptor-mutated NSCLC or HR+/HER2-negative breast cancer.
Resumption of Other Clinical Trials
Fortunately, recruitment for the aforementioned trial was able to resume in August. The focus shifted to utilizing dose levels not exceeding 3 mg/kg, particularly where the treatment has exhibited a manageable safety profile alongside encouraging clinical activity.
Current Market Sentiment
In light of the latest developments, the price action of BNTX stock reflected a slight decline, down 0.37% at $111.36 during the most recent market checks.
Frequently Asked Questions
What does the partial clinical hold imply for BioNTech's trial?
A partial clinical hold means that the FDA has temporarily stopped new patient enrollment while they review concerns regarding treatment outcomes.
How will current patients in the trial be affected?
Current patients enrolled in BioNTech's trial will continue to receive treatment uninterrupted.
What is the main focus of the PRESERVE-003 trial?
The PRESERVE-003 trial primarily investigates the efficacy of BNT316/ONC-392 as a standalone treatment for advanced non-small cell lung cancer.
Have there been similar holds in the past?
Yes, previous holds have occurred for other BioNTech trials, indicating that regulatory scrutiny is not uncommon in clinical research.
How is BioNTech addressing the FDA's concerns?
BioNTech is collaborating with the FDA to review the data and determine appropriate next steps for the trial moving forward.
